KPI builds sh182b laboratory
Mar 29, 2006
KAMPALA Pharmaceutical Industries (1996) Ltd has constructed a stability chamber laboratory worth $100,000 (sh182b) in Ntinda, Kampala, that will manufacture quality medicine.
By Ronald Kalyango
KAMPALA Pharmaceutical Industries (1996) Ltd has constructed a stability chamber laboratory worth $100,000 (sh182b) in Ntinda, Kampala, that will manufacture quality medicine.
During the launch of a new malaria drug, DUACT, the managing director and chief executive officer of KPI, Nazeem Mohamed, said the laboratory’s chambers would be used for stabilising drugs produced in the country.
“The failure to have a stability chamber in the country necessitated us to have them stabilised in either Europe or India so that they have a longer shelf life. Now that we have got the chambers, we shall do it from our premises,†Mohamed said.
He said they would also do stability work for other pharmaceutical companies if they (companies) get clearance from the National Drug Authority.
“This would help them minimise the costs and time spent to carry out the stability from abroad,†Mohamed said.
He said KPI is the largest manufacturer of pharmaceutical products in Uganda like anti-biotics, anti-malarials, cough and cold remedies and analgesics.
It became part of the Industrial Promotion Services (IPS), a subsidiary of the Aga Khan Development Network (AKDN) in 1996.
KAMPALA Pharmaceutical Industries (1996) Ltd has constructed a stability chamber laboratory worth $100,000 (sh182b) in Ntinda, Kampala, that will manufacture quality medicine.
During the launch of a new malaria drug, DUACT, the managing director and chief executive officer of KPI, Nazeem Mohamed, said the laboratory’s chambers would be used for stabilising drugs produced in the country.
“The failure to have a stability chamber in the country necessitated us to have them stabilised in either Europe or India so that they have a longer shelf life. Now that we have got the chambers, we shall do it from our premises,†Mohamed said.
He said they would also do stability work for other pharmaceutical companies if they (companies) get clearance from the National Drug Authority.
“This would help them minimise the costs and time spent to carry out the stability from abroad,†Mohamed said.
He said KPI is the largest manufacturer of pharmaceutical products in Uganda like anti-biotics, anti-malarials, cough and cold remedies and analgesics.
It became part of the Industrial Promotion Services (IPS), a subsidiary of the Aga Khan Development Network (AKDN) in 1996.